Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

about

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

Item

http://www.wikidata.org/entity/Q38037672

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

@en

type

Item

label

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

@en

prefLabel

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

@en

P1476

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

@en

P2093

Gurinder Rana

http://www.w3.org/2001/XMLSchema#string

Marc Cohen

http://www.w3.org/2001/XMLSchema#string

Zafar Iqbal

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Central role of the P2Y12 receptor in platelet activation

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

P304

181-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2174/157340312803217175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230739835

http://www.w3.org/2001/XMLSchema#string

P698

22920489

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

coronary thrombosis

P932

3465822

http://www.w3.org/2001/XMLSchema#string